Evidence Snapshot
What this grade covers
E reflects human/animal therapeutic efficacy for the exact doubly-modified compound (none established); D reflects identity/chemistry verification pending exact registry confirmation.
Regulatory Context
Not FDA-approved. No exact-compound clinical or regulatory record identified; sold only through research-peptide vendors.
Research Takeaway
PMID 27586814 studied N-terminally acetylated Semax chemistry; it is evidence about that acetylation, not automatically direct evidence for the additionally C-terminally amidated N-Acetyl Semax Amidate product unless the exact molecule studied is independently shown to match.
Evidence boundary: A single-acetylation chemistry paper does not establish efficacy or safety for the doubly-modified amidate product.
See all 2 evidence claims →Quick Summary
N-Acetyl Semax Amidate (commonly represented as Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2) is a doubly modified Semax analogue -- N-terminally acetylated and C-terminally amidated -- distinct from native Semax. A 2016 study (PMID 27586814) examined N-terminally acetylated Semax ("Ac-Semax") chemistry and showed that N-terminal acetylation changes Semax's chemical/biological behavior; that paper is evidence about acetylated-Semax chemistry only and is not automatically evidence for this additionally C-terminally amidated product, since the exact molecule studied has not been independently confirmed to match the commercial doubly modified compound. Native Semax's human/animal/BDNF/ischemia/dopamine evidence does not transfer to this analogue. No exact-compound human efficacy or safety study was identified. Claims of enhanced half-life or blood-brain-barrier penetration require direct pharmacokinetic evidence on the exact compound, which does not currently exist.
Mechanism & Research Overview
N-Acetyl Semax Amidate (commonly represented as Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2) is a doubly modified Semax analogue -- N-terminally acetylated and C-terminally amidated -- distinct from native Semax. A 2016 study (PMID 27586814) examined N-terminally acetylated Semax ("Ac-Semax") chemistry and showed that N-terminal acetylation changes Semax's chemical/biological behavior; that paper is evidence about acetylated-Semax chemistry only and is not automatically evidence for this additionally C-terminally amidated product, since the exact molecule studied has not been independently confirmed to match the commercial doubly modified compound. Native Semax's human/animal/BDNF/ischemia/dopamine evidence does not transfer to this analogue. No exact-compound human efficacy or safety study was identified. Claims of enhanced half-life or blood-brain-barrier penetration require direct pharmacokinetic evidence on the exact compound, which does not currently exist.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
PMID 27586814 studied N-terminally acetylated Semax chemistry; it is evidence about that acetylation, not automatically direct evidence for the additionally C-terminally amidated N-Acetyl Semax Amidate product unless the exact molecule studied is independently shown to match.
Does not establish
Evidence boundary: A single-acetylation chemistry paper does not establish efficacy or safety for the doubly-modified amidate product.
Supported
Native Semax's documented human/animal/BDNF/cerebral-ischemia/dopaminergic evidence does not transfer to N-Acetyl Semax Amidate, since N-terminal acetylation and C-terminal amidation change peptide stability and receptor interactions.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Research Areas Being Studied
Research areas discussed on this page reflect the Cognitive / Neuro category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
No Sources Listed Yet
Human, preclinical, regulatory, and review sources will appear here as they are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for N-Acetyl Semax Amidate
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.